Back HIV/AIDS

HIV / AIDS

IAS 2103: Dolutegravir Beats Raltegravir for Treatment-experienced HIV Patients [VIDEO]

The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir (Isentress), with fewer study withdrawal due to virological failure and less drug resistance, according to data from the SAILING trial presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose

Lowering the dosage of efavirenz (Sustiva) from 600 to 400 mg in an antiretroviral regimen did not compromise efficacy, and has the potential to substantially reduce treatment cost, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Experts Discuss Role of Drug Policy in HIV, Hepatitis, and TB Epidemics

International drug policy must shift from prohibition to public health in order to reduce harms to individuals and societies, including fueling the spread of HIV, hepatitis, and tuberculosis, experts from a range of disciplines agreed at 2 sessions held during the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.alt

IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV

The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir for previously treated people with HIV, with fewer study withdrawals due to virological failure and less emergent drug resistance, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Results were published concurrently in the July 3, 2013, online edition of The Lancet.

alt

IAS 2013: German Researchers Report Case of Functional Cure After Very Early HIV Treatment

Another case of prolonged control of HIV replication after stopping treatment was reported on this week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), indicating that cases of post-treatment control of HIV are not confined to the French VISCONTI cohort.

alt

IAS 2013: WHO Guidelines Call for Earlier HIV Treatment [VIDEO]

The World Health Organization (WHO) issued new global guidelines for antiretroviral therapy on June 30 at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.

alt

IAS 2013: Starting Treatment with CD4s Above 500 Reduces HIV Reservoir during Long-term Infection

People with HIV who start treatment with CD4 counts above 500 cells/mm3, after the first phase of primary infection is over, are much more likely to experience substantial reductions in the reservoir of HIV-infected cells in their bodies, making them strong candidates for future studies that seek to control HIV without medication, French researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt